Literature DB >> 16005514

Maturation-associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes.

Elisangela Ribeiro1, Sergio Matarraz Sudón, María de Santiago, Carmen S P Lima, Konradin Metze, Manuel Giralt, Sara T O Saad, Alberto Orfao de Matos, Irene Lorand-Metze.   

Abstract

Recent studies concerning the pathophysiology of myelodysplastic syndromes (MDS) have shown evidences for the existence of complex interactions between hematopoietic stem cells and the bone marrow (BM) microenvironment. We analyzed the B-lymphocyte maturation in BM of patients with MDS. For this purpose, 41 newly-diagnosed patients were analyzed. Enumeration and characterization of CD34+ and CD34- B-cell precursors and mature B-lymphocytes was performed using multiparameter flow cytometry. BM from eight transplant donors and six orthopedic surgery patients were used as controls. CD34+/CD45(lo) B-cells were found in 17/22 patients with RA/RARS and in 5/13 with RAEB. In patients with RAEB-t and CMML no CD34+ B-cell precursors could be detected. A positive correlation was found between CD34+ and CD34- B-cell precursors (r=0.52). CD34+ B-cell precursors presented an inverse correlation with BM percentage of blasts and peripheral leukocytes and a positive one with hemoglobin. Asynchronous antigen expression (CD19+/CD79a- cells) was found in 7/11 cases of RA/RARS and 6/18 cases of RAEB in which this phenotype was examined. Abnormal patterns of expression for at least one antigen was found in 91% of RA/RARS cases and in 74% of RAEB. Underexpression of TdT and CD79a were the most frequent abnormalities. Our results present evidences of an abnormal B-cell maturation in MDS. This may be an evidence that B-lymphocytes are derived of the abnormal clone. But it may also be the consequence of influences of abnormalities of BM microenvironment leading to an impaired commitment and maturation of the B-cell line in MDS. Studies performed with purified well-characterized B-cells may further elucidate these abnormalities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16005514     DOI: 10.1016/j.leukres.2005.05.019

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  8 in total

1.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

2.  Knockdown of Hspa9, a del(5q31.2) gene, results in a decrease in hematopoietic progenitors in mice.

Authors:  Tim H-P Chen; Amal Kambal; Kilannin Krysiak; Mark A Walshauser; Gagan Raju; Justin F Tibbitts; Matthew J Walter
Journal:  Blood       Date:  2010-12-01       Impact factor: 22.113

3.  Impact of bone marrow hematogones on umbilical cord blood transplantation outcomes in patients with acute myeloid leukemia.

Authors:  Theodore Honebrink; Vanessa Dayton; Michael J Burke; Karen Larsen; Qing Cao; Claudio Brunstein; Daniel Weisdorf; Jeffery S Miller; John E Wagner; Michael R Verneris
Journal:  Biol Blood Marrow Transplant       Date:  2011-11-20       Impact factor: 5.742

4.  Hematogones: a sensitive prognostic factor for Chinese adult patients with acute myeloid leukemia.

Authors:  L Li; R Fu; T Zhang; X Xie; J Liu; J Tao; J Song; H Liu; W Zhang; W Lu; Z Shao
Journal:  Curr Oncol       Date:  2016-04-13       Impact factor: 3.677

5.  Reduced CD38 expression on CD34+ cells as a diagnostic test in myelodysplastic syndromes.

Authors:  Nicolas Goardon; Emmanouil Nikolousis; Alexander Sternberg; Wai-Kit Chu; Charles Craddock; Peter Richardson; Richard Benson; Mark Drayson; Graham Standen; Paresh Vyas; Sylvie Freeman
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

6.  Association of myelodysplastic syndrome with CD5+, CD23+ monoclonal B-cell lymphocytosis.

Authors:  Alex F Sandes; Maria de Lourdes L F Chauffaille; Alberto Orfao; Graziella C Siufi; Maria Regina R Silva; Mihoko Yamamoto
Journal:  Clinics (Sao Paulo)       Date:  2012-12       Impact factor: 2.365

7.  Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors.

Authors:  Suiellen C Reis-Alves; Fabiola Traina; Konradin Metze; Irene Lorand-Metze
Journal:  Diagn Pathol       Date:  2015-04-29       Impact factor: 2.644

8.  Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores.

Authors:  Suiellen C Reis-Alves; Fabíola Traina; Guilherme Harada; Paula M Campos; Sara T O Saad; Konradin Metze; Irene Lorand-Metze
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.